Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SLO-BID vs ELIXOMIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Relaxes smooth muscle of bronchial airways and pulmonary blood vessels by inhibiting phosphodiesterase, increasing intracellular c AMP, and promoting bronchodilation.
ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.
Treatment of asthma,Treatment of chronic obstructive pulmonary disease (COPD)
Treatment of refractory epilepsy,Adjunctive therapy for complex partial seizures,Off-label: neuropathic pain management,Off-label: bipolar disorder maintenance
Dose: 300-600 mg orally every 12 hours. Immediate-release: 5 mg/kg loading dose then 3 mg/kg every 6 hours. Extended-release: 10-15 mg/kg/day divided every 12 hours. Titrate to serum theophylline concentration of 5-15 mcg/m L.
500 mg orally once daily with a full glass of water, regardless of meals.
Terminal elimination half-life: 3-15 hours (mean ~10 hours in adults; 20-30 hours in neonates; 1-5 hours in smokers). Clinically, half-life decreases with smoking, increases with hepatic disease, heart failure, and certain drugs (e.g., cimetidine, ciprofloxacin).
Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by CYP2E1 and xanthine oxidase.
Primarily metabolized by CYP3A4 and CYP2C19 isoenzymes; undergoes glucuronidation via UGT1A4. Active metabolite: N-desethyl-ELIXOMIN.
Renal: 90% as metabolites (caffeine, theobromine, paraxanthine, and unchanged drug; 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine). Biliary/fecal: <10%.
Renal elimination of unchanged drug accounts for 60-70% of clearance; biliary/fecal excretion accounts for 20-25%; the remainder is metabolized hepatically with inactive metabolites excreted renally.
~40% bound to albumin.
98% bound to albumin and alpha-1-acid glycoprotein.
0.45 L/kg (range 0.3-0.7 L/kg). Distributes into total body water; higher Vd in neonates and patients with hepatic cirrhosis.
0.6-0.8 L/kg; distributes rapidly into total body water, with moderate tissue binding.
Oral immediate-release: 96-100%; oral sustained-release: 90-100% (relative to immediate-release, with dose dumping risk if formulation is altered).
Oral: 70-80% (due to first-pass metabolism); Intramuscular: 90-95%.
No routine adjustment needed. Monitor for accumulation in severe impairment (Cr Cl <10 m L/min) and consider reducing dose or extending interval.
GFR > 60 m L/min: no adjustment; GFR 30-60 m L/min: 250 mg once daily; GFR 15-29 m L/min: 125 mg once daily; GFR < 15 m L/min or dialysis: not recommended.
Child-Pugh Class A: reduce dose by 50%; Class B or C: reduce dose by 50-75% and monitor levels.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% (250 mg once daily); Class C: not recommended.
Children 1-9 years: 20-24 mg/kg/day orally divided every 12 hours; children 9-12 years: 20 mg/kg/day; adolescents 12-16 years: 18 mg/kg/day. Use ideal body weight. Adjust based on serum theophylline levels.
Weight ≥ 40 kg: 500 mg once daily; Weight 20-39 kg: 250 mg once daily; Weight < 20 kg: not established.
Start at lower end of dosing range (e.g., 300 mg/day) due to decreased clearance. Titrate slowly and monitor serum concentrations. Avoid sustained-release formulations if hepatic impairment present.
No specific dose adjustment except based on renal function. Monitor for increased risk of QT prolongation and electrolyte disturbances. Initial dose should be 250 mg once daily if Cr Cl < 60 m L/min.
Theophylline has a narrow therapeutic index. Severe and fatal toxicities can occur if serum concentrations exceed 20 mcg/m L. Serum levels must be closely monitored during therapy.
WARNING: Risk of suicidal thoughts and behaviors; monitor for worsening depression or emergence of suicidal ideation.
Serious and life-threatening adverse reactions including seizures and cardiac arrhythmias can occur at serum levels above 20 mcg/m L.,Concomitant use with other xanthine derivatives may increase toxicity.,Use with caution in patients with peptic ulcer, seizures, cardiac disease, or hepatic impairment.
Hepatotoxicity (monitor LFTs); hematologic effects (thrombocytopenia, neutropenia); severe dermatologic reactions (SJS/TEN); pancreatitis; hyperammonemia; somnolence and dizziness; withdrawal seizures upon abrupt discontinuation.
Hypersensitivity to theophylline or any component of the formulation,Uncontrolled seizure disorders,Active gastrointestinal hemorrhage
Absolute: Hypersensitivity to ELIXOMIN or any component; history of drug-induced liver injury; concomitant use with MAOIs. Relative: Hepatic impairment; renal insufficiency (Cr Cl <30 m L/min); pregnancy (teratogenic effects in animal studies).
High-fat meals may reduce the rate of absorption but not extent; take consistently with or without food. Avoid charcoal-broiled foods and large amounts of dietary protein, which can increase clearance. Grapefruit juice may increase theophylline levels (minor effect).
Grapefruit and grapefruit juice significantly increase ELIXOMIN plasma concentrations, increasing risk of toxicity. High-potassium foods (e.g., bananas, oranges, spinach) should be limited due to risk of hyperkalemia.
SLO-BID (theophylline) is classified as FDA Pregnancy Category C. First trimester: Limited human data, but no clear teratogenic pattern observed. Second and third trimesters: Theophylline crosses the placenta; maternal toxicity may cause fetal adverse effects such as transient tachycardia, jitteriness, and vomiting in neonates. Apnea and seizures reported in cases of maternal overdose.
ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second and third trimesters: Increased risk of spontaneous abortion, preterm delivery, and fetal growth restriction due to uteroplacental insufficiency.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.6–0.7. The relative infant dose is about 10% of the maternal weight-adjusted dose. Although generally considered compatible with breastfeeding, monitor the infant for signs of irritability, insomnia, or poor feeding, especially at higher maternal doses or with multiple doses.
Not recommended during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infant (e.g., nephrotoxicity, ototoxicity).
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased volume of distribution, potentially requiring dose increases of up to 20–40% to maintain therapeutic serum concentrations. However, clearance decreases near term and postpartum, necessitating dose reduction. Frequent monitoring of serum levels is critical to avoid toxicity.
Due to increased glomerular filtration rate (GFR) in pregnancy, higher doses of ELIXOMIN may be required to achieve therapeutic drug levels. However, given teratogenicity, use is contraindicated; alternative therapy should be considered.
SLO-BID (theophylline) requires serum level monitoring (therapeutic range 10-20 mcg/m L); levels >20 may cause toxicity. Use with caution in heart failure, hepatic impairment, or elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides increase levels; rifampin, phenytoin, smoking decrease levels. Sustained-release formulation avoids peak-trough fluctuations and improves adherence.
Monitor serum potassium levels closely; ELIXOMIN can cause life-threatening hyperkalemia especially in patients with renal impairment. Avoid concurrent use with potassium-sparing diuretics.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Avoid excessive caffeine intake (coffee, tea, cola) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, restlessness, insomnia, or rapid heartbeat.,Do not stop abruptly; taper under medical supervision to prevent rebound symptoms.,Maintain consistent timing; missed doses should be taken if remembered within 2 hours, otherwise skip.
Do not consume grapefruit or grapefruit juice while taking ELIXOMIN.,Take with food to reduce gastrointestinal upset.,Report any muscle cramps, palpitations, or irregular heartbeat immediately.,Avoid potassium supplements and salt substitutes containing potassium.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SLO-BID vs ELIXOMIN, answered by our medical review team.
SLO-BID is a Xanthine Bronchodilator that works by Relaxes smooth muscle of bronchial airways and pulmonary blood vessels by inhibiting phosphodiesterase, increasing intracellular c AMP, and promoting bronchodilation.. ELIXOMIN is a Xanthine Bronchodilator that works by ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SLO-BID and ELIXOMIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SLO-BID is: Dose: 300-600 mg orally every 12 hours. Immediate-release: 5 mg/kg loading dose then 3 mg/kg every 6 hours. Extended-release: 10-15 mg/kg/day divided every 12 hours. Titrate to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of ELIXOMIN is: 500 mg orally once daily with a full glass of water, regardless of meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SLO-BID and ELIXOMIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SLO-BID is classified as Category C. SLO-BID (theophylline) is classified as FDA Pregnancy Category C. First trimester: Limited human data, but no clear teratogenic pattern observed. Second and third trimesters: Theop. ELIXOMIN is classified as Category C. ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.